Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:120 |
Name | female reproductive organ cancer |
Definition | A reproductive organ cancer that is manifested in the female genitals. This includes organs such as the ovaries, fallopian tubes, uterus, cervix, vagina and vulva. |
Source | DiseaseOntology.org |
Alt Ids | DOID:1244 DOID:1281 |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA mutant | Capivasertib | female reproductive organ cancer | predicted - sensitive | detail... |
BRAF D594N | Trametinib | female reproductive organ cancer | no benefit | detail... |
BRAF N581S | Trametinib | female reproductive organ cancer | no benefit | detail... |
NRAS mutant | Navitoclax + Trametinib | female reproductive organ cancer | sensitive | detail... |
PIK3CA act mut | Alpelisib | female reproductive organ cancer | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00800345 | Phase I | Pazopanib + Topotecan | Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors | Completed | USA | 0 |
NCT01831089 | Phase I | Bevacizumab + Lurbinectedin + Paclitaxel Lurbinectedin + Paclitaxel | Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | Completed | USA | ESP | CHE | 0 |
NCT03073525 | Phase II | Atezolizumab + FANG vaccine | Trial of Atezolizumab and Vigil for Advanced Gynecological Cancers (A Companion Study to CL-PTL-119) | Completed | USA | 0 |
NCT03277482 | Phase I | Durvalumab + Tremelimumab Durvalumab | Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer | Terminated | USA | 0 |
NCT04042116 | Phase Ib/II | Lucitanib + Nivolumab | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | Suspended | USA | ITA | ESP | DEU | BEL | AUT | 0 |
NCT04273061 | Phase II | Atezolizumab | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8) | Recruiting | CAN | 0 |
NCT04395079 | Phase II | Tremelimumab Durvalumab | Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies | Active, not recruiting | USA | 0 |
NCT04682431 | Phase I | Pembrolizumab + PY159 PY159 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT05238922 | Phase I | INCB123667 | Study of INCB123667 in Subjects With Advanced Solid Tumors | Recruiting | USA | NLD | ITA | GBR | FRA | CHE | 1 |
NCT05512208 | Phase II | Defactinib + RO5126766 | A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib (DURAFAK) | Recruiting | USA | 0 |
NCT05564377 | Phase II | Selumetinib Binimetinib + Fulvestrant Binimetinib + Palbociclib Nilotinib + Paclitaxel Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Panitumumab + Sotorasib Binimetinib Fulvestrant Olaparib Olaparib + Selumetinib Alpelisib + Olaparib Neratinib Neratinib + Palbociclib Fluorouracil + Leucovorin + Oxaliplatin Ipatasertib + Paclitaxel | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Recruiting | USA | 1 |
NCT05636215 | Phase Ib/II | IBI354 | A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | Recruiting | AUS | 1 |
NCT05704985 | Phase I | DK210 DK210 + Nivolumab Paclitaxel DK210 + Pembrolizumab Oxaliplatin Capecitabine Fluorouracil Carboplatin | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | Recruiting | USA | 0 |
NCT05768139 | Phase Ib/II | Fulvestrant + STX-478 STX-478 | First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | 0 |
NCT05787561 | Phase II | Defactinib + RO5126766 | A Study of VS-6766 and Defactinib in People With Mesonephric Gynecologic Cancer | Recruiting | USA | 0 |
NCT06126276 | Phase II | Neratinib Neratinib + Palbociclib | Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) | Recruiting | USA | 0 |
NCT06307249 | Phase I | Bevacizumab + Palbociclib | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA (PTST_PALBEVA) | Recruiting | LBN | 0 |